Condition: Pancreatic Ductal Adenocarcinoma · Sponsor: Gulam Manji
The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to evade the immune system (CD73 and A2a/b). The study hopes that these drugs will work in concert with radiation therapy to kill cancer cells. The specific goal of this study is to ensure that treatment with zimberelimab and stereotactic body radiation therapy (SBRT) alone or in combination with quemliclustat (a drug which blocks CD73), with or without etrumadenant (a drug which blocks the A2a/b) given before surgery is safe and if it can further increase the immune response against the tumor.
This description comes directly from the study's public registry record.
Research Nurse Navigator · 212-342-5162 · cancerclinicaltrials@cumc.columbia.edu
Always discuss trial participation with your own doctor first.
| Northwell Health R.J. Zuckerberg Cancer Center | Lake Success, New York, United States | Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
| UNC Hospitals, The University of North Carolina at Chapel Hill | Chapel Hill, North Carolina, United States | Recruiting |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06048484